ALISO VIEJO, Calif., Feb. 13, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc., an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd., has reached an agreement in principle to resolve an investigation by the United States Department of Justice related to certain of Avanir's sales and marketing practices for its product NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules prior to 2017. The announcement was first made today by Otsuka in Japan. The agreement in principle is contingent upon the parties' negotiation and execution of civil, criminal and administrative agreements.
Until the agreements with the government are finalized, Avanir will not be able to provide additional details. Avanir will provide more information regarding this matter once those agreements are executed.
About Avanir Pharmaceuticals, Inc.
Avanir is committed to delivering innovative central nervous system (CNS) solutions to improve the lives of patients and their care communities. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing CNS treatments in areas of high unmet medical need. For more information about Avanir, please visit http://www.avanir.com.
In 2015 Avanir became a subsidiary of Otsuka America, Inc. (OAI), a holding company that is wholly owned by Otsuka Pharmaceutical Co., Ltd., a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.'
View original content to download multimedia:http://www.prnewswire.com/news-releases/avanir-pharmaceuticals-inc-reaches-agreement-in-principle-with-us-department-of-justice-regarding-nuedexta-dextromethorphan-hbr-and-quinidine-sulfate-20mg10mg-capsules-300794735.html